Revenue
No reported data
Aprea Therapeutics, Inc. (APRE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | $7.0M | $9.4M | $7.6M | $16.4M | $23.9M | $37.9M | $21.0M | $14.2M | $13.4M |
| Operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M | $52.8M | $29.5M | $16.5M | $15.9M |
| Operating income | −$13.2M | −$14.3M | −$15.5M | −$113.4M | −$37.4M | — | — | — | — |
| EBITDAderived | −$13.2M | −$14.3M | −$15.5M | −$113.4M | −$37.4M | — | — | — | — |
| Net income | −$12.6M | −$13.0M | −$14.3M | −$112.7M | −$37.1M | −$53.5M | −$28.1M | −$15.5M | −$15.2M |
| Basic EPSper diluted share | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$4.67 | -$13.45 | -$13.17 |
| Diluted EPSper diluted share | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$4.67 | -$13.45 | -$13.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | BuyCommon Warrant · derivative | 31.0K | — | — | 31.0K |
| Mar 31, 2026Form 4 | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | BuyPre-Funded Warrant · derivative | 31.0K | $0.81 | $25.1K | 31.0K |
| Mar 31, 2026Form 4 | Peters RichardDirector | BuyCommon Warrant · derivative | 123.9K | — | — | 123.9K |
| Mar 31, 2026Form 4 | Peters RichardDirector | BuyPre-Funded Warrant · derivative | 123.9K | $0.81 | $100.4K | 123.9K |
| Jan 30, 2026Form 4 | Gilad OrenPresident/CEO | BuyCommon Stock | 28.1K | $0.89 | $25.0K | 373.7K |